Quiz 10 Flashcards
tamoxifen 1
Brand: Nolvadex, Soltamox
Class: Antineoplastic Agent, Estrogen Receptor Antagonist; Selective Estrogen Receptor Modulator (SERM)
Indication: Breast cancer
tamoxifen 2
MOA: Acts as a SERM, acting as an estrogen antagonist in breast tissue and an estrogen agonist in liver and bone tissue
BBW: Serious life-threatening events associated with ductal carcinoma in situ/women at high risk for breast cancer
SE: vasodilation, flushing, HTN, peripheral edema, mood changes, pain, depression, skin changes, rash, hot flashes, fluid retention, altered menses, amenorrhea, N/V, weight loss, vaginal discharge/bleeding, weakness, arthritis, arthralgia, pharyngitis, lymphedema
anastrozole 1
Brand: Arimidex
Class: Antineoplastic Agent, Aromatase Inhibitor
Indication: Breast cancer
anastrozole 2
MOA: Potent and selective nonsteroidal aromatase inhibitor. By inhibiting aromatase, the conversion of androstenedione to estrone, and testosterone to estradiol, is prevented, thereby decreasing tumor mass or delaying progression in patients with tumors responsive to hormones. Anastrozole causes an 85% decrease in estrone sulfate levels.
BBW: N/A
SE: vasodilation, ischemic heart disease, HTN, angina pectoris, edema, fatigue, mood disorder, HA, pain, depression, skin rash, hot flash, GI distress, N/V, weakness, arthritis, arthralgia, back pain, ostealgia, osteoporosis, pharyngitis, dyspnea, increased cough
trastuzumab 1
Brand: Herceptin
Class: Antineoplastic Agent, Anti-HER2; Antineoplastic Agent, Monoclonal Antibody
Indication: Adjuvant to breast cancer, metastatic breast cancer, metastatic gastric cancer
trastuzumab 2
MOA: Trastuzumab is a monoclonal antibody which binds to the extracellular domain of the human epidermal growth factor receptor 2 protein (HER-2); it mediates antibody-dependent cellular cytotoxicity by inhibiting proliferation of cells which overexpress HER-2 protein
BBW: Cardiomyopathy, infusion reactions and pulmonary toxicity, embryo-fetal toxicity
SE: decreased left ventricular ejection fraction, pain, chills, HA, insomnia, dizziness, skin rash, N/V/D, abdominal pain, anorexia, infection, weakness, back pain, cough, dyspnea, rhinitis, pharyngitis, infusion related reaction, fever
rituximab 1
Brand: Rituxan
Class: Antineoplastic Agent, Anti-CD20; Antineoplastic Agent, Monoclonal Antibody; Antirheumatic, Miscellaneous; Immunosuppressant Agent; Monoclonal Antibody
Indication: CD20-positive Non-Hodgkin’s Lymphoma, CD20-positive CLL, rheumatoid arthritis, granulomatosis with polyangiitis, microscopic polyangiitis (MPA)
rituximab 2
MOA: Rituximab is a monoclonal antibody directed against the CD20 antigen on B-lymphocytes. CD20 regulates cell cycle initiation; and, possibly, functions as a calcium channel. Rituximab binds to the antigen on the cell surface, activating complement-dependent B-cell cytotoxicity; and to human Fc receptors, mediating cell killing through an antibody-dependent cellular toxicity. B-cells are believed to play a role in the development and progression of rheumatoid arthritis. Signs and symptoms of RA are reduced by targeting B-cells and the progression of structural damage is delayed
BBW: Fatal infusion reactions, severe mucocutaneous infections, HBV reactivation, progressive multifocal leukoencephalopathy
SE: peripheral edema, HTN, fever, fatigue, chills, HA, insomnia, rash, pruritus, angioedema, N/D, abdominal pain, weight gain, cytopenias, anemia, neutropenia, ALT increased, neuropathy, weakness, muscle spasms, arthralgia, cough, rhinitis, epistaxis
erlotinib 1
Brand: Tarceva
Class: Antineoplastic Agent, Epidermal Growth Factor Receptor (EGFR) Inhibitor; Antineoplastic Agent, Tyrosine Kinase Inhibitor
Indication: Non-small cell lung cancer (NSCLC), pancreatic cancer
erlotinib 2
Mechanism of action: Reversibly inhibits overall epidermal growth factor receptor (HER1/EGFR) - tyrosine kinase activity. Intracellular phosphorylation is inhibited which prevents further downstream signaling, resulting in cell death. Erlotinib has higher binding affinity for EGFR exon 19 deletion or exon 21 L858R mutations than for the wild type receptor.
BBW: N/A
Side effects: chest pain, fatigue, skin rash, , paronychia, alpecia, acne vulgaris, N/V/D, anorexia, decreased appetite, mucositis, abdominal pain, constipation, UTI, anemia, increased susceptibility to infection, fever, wekaness, back pain, arthralgia, musculoskeletal pain, conjunctivitis, cough, dyspnea
imatinib 1
Brand: Gleevec
Class: Antineoplastic Agent, BCR-ABL Tyrosine Kinase Inhibitor; Antineoplastic Agent, Tyrosine Kinase Inhibitor
Indication: GI stromal tumors, Ph (+) CML, Ph (+) ALL, aggressive systemic mastocytosis (ASM), dermatofibrosarcoma protuberans (DFSP), hypereosinophilic syndrome +/- chronic eosinophilic leukemia (CEL), myelodysplastic/myeloproliferative disease (MDS/MPD)
imatinib 2
MOA: Inhibits Bcr-Abl tyrosine kinase, the constitutive abnormal gene product of the Philadelphia chromosome in chronic myeloid leukemia (CML). Inhibition of this enzyme blocks proliferation and induces apoptosis in Bcr-Abl positive cell lines as well as in fresh leukemic cells in Philadelphia chromosome positive CML. Also inhibits tyrosine kinase for platelet-derived growth factor (PDGF), stem cell factor (SCF), c-Kit, and cellular events mediated by PDGF and SCF.
BBW: N/A
SE: A lot
bevacizumab 1
Brand: Avastin
Class: Antineoplastic Agent, Monoclonal Antibody; Antineoplastic Agent, Vascular Endothelial Growth Factor (VEGF) Inhibitor; Vascular Endothelial Growth Factor (VEGF) Inhibitor
Indication: cervical cancer, colorectal cancer, glioblastoma, NSCLC, renal cell carcinoma
bevacizumab 2
Mechanism of action: Bevacizumab is a recombinant, humanized monoclonal antibody which binds to, and neutralizes, vascular endothelial growth factor (VEGF), preventing its association with endothelial receptors, Flt-1 and KDR. VEGF binding initiates angiogenesis (endothelial proliferation and the formation of new blood vessels). The inhibition of microvascular growth is believed to retard the growth of all tissues (including metastatic tissue)
BBW: GI perforations, surgery and wound healing complications, hemorrhage
Side effects: HTN, thrombosis, hypotension, pain, fatigue, HA, dizziness, taste disorder, neuropathy, alopecia, xeroderma, exfoliative dermatitis, skin discoloration, ovarian failure, weight loss, abdominal pain, proteinuria, hemorrhage, leukopenia, neutropenia, infection, myalgia, upper respiratory tract infection
cetuximab 1
Brand: Erbitux
Class: Antineoplastic Agent, Epidermal Growth Factor Receptor (EGFR) Inhibitor; Antineoplastic Agent, Monoclonal Antibody
Indication: Treatment of KRAS mutation-negative (wild-type), EGFR-expressing metastatic colorectal cancer
